Paul Romness, chair, chief executive officer, and president of OS Therapies, discusses how advances in linker chemistry, payload design, and evolving regulatory approaches could shape the next generation of antibody–drug conjugates for oncology.
Paul Romness
Advertisement
Paul Romness, MHP, is chair and CEO of OS Therapies, a company developing novel immunotherapies for cancers like osteosarcoma and other solid tumors.
Articles by Paul Romness
Advertisement
Latest Updated Articles
Advertisement
Advertisement